HEALTH● LOWOct 2 · Oct 2, 2026, 9:27 PM
FDA extends review for Novo Nordisk's denecimig for hemophilia A
Seeking Alpha Tech · north america
The FDA has extended its review period for Novo Nordisk's drug denecimig, intended for the treatment of hemophilia A. This extension indicates further evaluation is required for the pharmaceutical product.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH38m agoThe health of Leo XIV: the Pope advances in his recovery, but uncertainty remains about his visit to South AmericaClarínHEALTH52m agoHealthcare workers protest in virtually every state over pay, shortages and staffingMexico News DailyHEALTH1h agoKFF: Individual health insurance enrollment fell 18 percent in JuneThe HillHEALTH2h agoPaxton suing Gerber and Nestlé over alleged arsenic and lead in baby foodThe Hill